Spots Global Cancer Trial Database for Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors
Official Title: A Phase 1/2, Open-Label, Dose-Escalation and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-999 in Patients With Advanced Solid Tumors
Study ID: NCT04084366
Conditions
Study Description
Brief Summary: The purpose of this study is to establish the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of OBI-999 as monotherapy, and to characterize the safety and preliminary clinical activity profile of the RP2D of OBI-999 in patients with advanced solid tumors.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Scripps MD Anderson Cancer Center, La Jolla, California, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
West Cancer Center, Germantown, Tennessee, United States
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Contact Details
Name: Apostolia Tsimberidou, MD, PhD
Affiliation: M.D. Anderson Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
